A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Fasinumab (Primary)
- Indications Pain
- Focus Pharmacodynamics
- Sponsors Regeneron Pharmaceuticals
- 26 Nov 2019 Planned End Date changed from 28 Aug 2020 to 18 Dec 2020.
- 26 Nov 2019 Planned primary completion date changed from 27 Sep 2019 to 17 Jan 2020.
- 26 Nov 2019 Status changed from recruiting to active, no longer recruiting.